1.Clinical research of T lymphocyte subgroup in patients with multiple sclerosis
Liping WU ; Shunxiu WU ; Ming CHEN ; Senmei LI ; Xuan ZHENG
Journal of Chinese Physician 2002;0(S1):-
Objective To explore significance of the T lymphacyte subgroup in cases with multiple sclerosis(MS).Methods Indirect immunofluorescence assay and flow cytometry were used to evaluate the presence of CD_4~+,CD_8~+ and T lymphocyte in the sera and CSF in patients with MS treated with glucocorticoid in the active stage.Results The CD_4~+,CD_8~+ and T lymphocyte in the peripheral blood of the patients in comparison with those of the control group decreased whereas their CD_4~+/CD_8~+ increased(P
2.Prediction of malignant middle cerebral artery infarction by plasma MMP-9 and hsCRP level
Shunxiu WU ; Wen LI ; Lingling ZHANG ; Weiduan ZHUANG ; Xuan ZHENG ; Yingxiu XIAO ; Rongbo CHEN
Chinese Journal of Primary Medicine and Pharmacy 2010;17(10):1303-1305
Objective To evaluate the predicting value of the marker of endothelial injury: plasma matrix metalloproteinase-9( MMP-9) and high sensitivity C-reactive protein( hsCRP) level on the progression of acute anterior circulating territory infarction progressing to malignant middle cerebral artery infarction (m-MCAI). Methods 90 patients with acute anterior circulating territory infarction, in which 46 patients progressed to m-MCAI, were collected and sampled consecutively. The plasma MMP-9 and hsCRP of all patients were determined by ELISA and immunotur-bidimetry,respectively,at admission. And the clinical characters and cranial CT features of the patients were analyzed. Results At admission,the plasma MMP-9 level in the patients with m-MCAI(242.0 ±58.0)ng/ml was significantly higher than that in the patients with non m-MCAI( 169.0 ± 50.0) ng/ml( P < 0. 01) ,the plasma hsCRP level in the patients with m-MCAI(6.25 ±1.2) ng/ml was significantly higher than that in the patients with non m-MCAI( 1.55 ± 0.9) mg/ml( P <0. 01).Conclusion The increased level of plasma MMP-9 and hsCRP could be predictors for the m-MCAI proceeding.